Search results
Breakthrough antidepressants with fewer side effects could help millions of Americans. Here’s what...
Fortune via Yahoo Finance· 8 months agoAs Americans are increasingly reaching for pharmaceutical solutions for depression—about one in...
FDA Approves First Fast-Acting Drug for Depression That Works Within 1 Week
Prevention via Yahoo News· 2 years agoThe FDA approves an oral medication to treat clinical depression: Auvelity from Axsome Therapeutics....
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Motley Fool· 1 year agoAxsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two...
Common Medications Used to Treat Major Depressive Disorder
Verywell Health via Yahoo News· 5 months agoMajor depressive disorder (MDD), also referred to as clinical depression or simply depression, is a...
How Treatment-Resistant Depression is Treated
Verywell Mind via Yahoo News· 2 years agoTreatment-resistant depression (TRD) is defined as depression that does not adequately respond after trying at least two medications. TRD is not an...
3 Top Healthcare Stocks to Buy for November
Motley Fool· 2 years agoCRISPR Therapeutics (NASDAQ: CRSP) is submitting what may become its first commercialized gene-editing treatment to regulators this month. Axsome...
If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now
Motley Fool· 1 year agoSome stocks soar overnight. But in most cases, you'll have a better chance of winning in the stock...
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
Motley Fool· 2 years agoTwo biotech companies are great examples of this: giant Vertex Pharmaceuticals (NASDAQ: VRTX) and...
After Jumping 100%, Is Axsome a Buy Before 2023?
Motley Fool· 2 years agoAxsome Therapeutics (NASDAQ: AXSM) has done something most other stocks haven't been able to do this year: It's beaten the bear market. The company...
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
Motley Fool· 1 year agoAxsome Therapeutics (NASDAQ: AXSM) soared more than 100%. Vertex submitted a potential blockbuster...
